本文關(guān)鍵詞： 認(rèn)知功能損害 Ⅲ期臨床試驗(yàn) 激動(dòng)劑 安慰劑對(duì)照 試驗(yàn)點(diǎn) 皮層神經(jīng)元 共主 神經(jīng)認(rèn)知 臨床療效 評(píng)分表 　出處：《國(guó)際藥學(xué)研究雜志》2016年04期 　論文類型：期刊論文

【摘要】：正FORUM制藥有限公司宣布更新其2次煙堿型乙酰膽堿受體激動(dòng)劑encenicline治療精神分裂癥認(rèn)知功能損害的Ⅲ期臨床試驗(yàn)資料,證實(shí)安全性和耐受性較佳,但均未能達(dá)到共主終點(diǎn)認(rèn)知功能損害和患者功能較安慰劑組明顯改善,這是由于安慰劑組也有較高有效率的影響,故結(jié)果尚需進(jìn)一步分析。encenicline的26周Ⅲ期臨床試驗(yàn),包括2個(gè)平行、隨機(jī)、雙盲、安慰劑對(duì)照的研究,在200個(gè)試驗(yàn)點(diǎn)中評(píng)價(jià)了1500名精神分裂
[Abstract]:FORUM Pharmaceutical Co., Ltd. announced the update of its two nicotinic acetylcholine receptor agonist encenicline in the treatment of schizophrenia cognitive impairment phase III clinical trial data. It was proved that the safety and tolerance were better, but both of them failed to reach the common end point cognitive impairment and the patients' function was significantly improved compared with the placebo group, which was due to the effect of higher efficiency in the placebo group. Therefore, further analysis of .encenicline 's 26-week phase 鈪，

本文編號(hào)：1480868